Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate with or without berberine hydrochloride in early rheumatoid arthritis
ChiCTR2400085087Phase 2Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of berberine and methotrexate in rheumatoid arthritis (RA) (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: ACR20 response rate at 12 weeks. Planned start May 2024; status: not yet recruiting.
02
Drugs
berberinemethotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR2400085087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085087.